Form 4: Phibro CEO Jack Bendheim Executes Stock Sale Plan

Phibro Animal Health Corporation CEO Jack Bendheim and BFI Co., LLC sold shares of Class A Common Stock under a pre-established Rule 10b5-1 trading plan.

Summary

• CEO Jack Bendheim and BFI Co., LLC sold a total of 20,520 shares of Class A Common Stock between April 14 and April 16, 2026.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025.
• On April 16, 2026, 100,000 shares of Class B Common Stock were converted into Class A Common Stock on a one-for-one basis.
• Following these transactions, BFI Co., LLC retains 117,000 shares of Class A Common Stock, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the transactions are routine insider activity conducted under a pre-established plan, which does not reflect a change in the company's fundamental outlook.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The sale of shares by a CEO and 10% owner may be perceived by some investors as a reduction in long-term alignment or a signal of profit-taking.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity by major shareholders could lead to periodic downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a disclosure of insider ownership changes.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a common practice in the animal health and pharmaceutical sectors, often used by executives to manage personal liquidity while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives at firms like Zoetis or Elanco to divest shares while avoiding insider trading allegations.

Related Party Transactions

• Transactions involve BFI Co., LLC, an entity over which Jack Bendheim exercises voting and dispositive power.

Stakeholder Impact

• Shareholders should note the reduction in direct and indirect holdings by the CEO, though the volume is relatively small compared to total ownership.

Next Steps

• Continued monitoring of future Form 4 filings to track further sales under the established 10b5-1 plan.

Key Dates

Keywords

Phibro Animal Health, PAHC, Insider Trading, Rule 10b5-1, Jack Bendheim, Stock Sale, Corporate Governance